BACKGROUND: The benefits of adding chemotherapy to surgery in patients with hepatic colorectal metastases at moderate and high risk for recurrence and the optimal sequence of administration are undetermined. METHODS: We followed the overall-survival and event-free survival rates after operation in patients with resectable colorectal metastases confined to the liver. The adjuvant patients first underwent surgery and then treatment, whereas the neoadjuvant patients underwent treatment, surgery, and re-treatment. Assignment was by oncologist and patient preferences. Chemotherapy was oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based. RESULTS: Fifty-six of 105 patients who underwent liver resections for colorectal metastases (2002-2005) are included. The two groups were comparable for demographics, characteristics of disease (including recurrence risk), treatment protocols, and follow-up. The respective 1-, 2-, and 3-year overall survival rates were 91%, 91%, and 84%, and the event-free survival rates were 63%, 49%, and 49% for the 19 adjuvant patients, and 95%, 91%, and 70%, and 94%, 50%, and 50% for the 37 neoadjuvant patients. CONCLUSIONS: The midterm overall survival and disease-free survival rates in this group of patients with resectable colorectal metastases to the liver, who were treated with combination of resection and chemotherapy, were similar, regardless of the sequence of treatment.
BACKGROUND: The benefits of adding chemotherapy to surgery in patients with hepatic colorectal metastases at moderate and high risk for recurrence and the optimal sequence of administration are undetermined. METHODS: We followed the overall-survival and event-free survival rates after operation in patients with resectable colorectal metastases confined to the liver. The adjuvant patients first underwent surgery and then treatment, whereas the neoadjuvant patients underwent treatment, surgery, and re-treatment. Assignment was by oncologist and patient preferences. Chemotherapy was oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based. RESULTS: Fifty-six of 105 patients who underwent liver resections for colorectal metastases (2002-2005) are included. The two groups were comparable for demographics, characteristics of disease (including recurrence risk), treatment protocols, and follow-up. The respective 1-, 2-, and 3-year overall survival rates were 91%, 91%, and 84%, and the event-free survival rates were 63%, 49%, and 49% for the 19 adjuvant patients, and 95%, 91%, and 70%, and 94%, 50%, and 50% for the 37 neoadjuvant patients. CONCLUSIONS: The midterm overall survival and disease-free survival rates in this group of patients with resectable colorectal metastases to the liver, who were treated with combination of resection and chemotherapy, were similar, regardless of the sequence of treatment.
Authors: A Wein; C Riedel; F Köckerling; P Martus; U Baum; W M Brueckl; T Reck; R Ott; J Hänsler; T Bernatik; D Becker; T Schneider; W Hohenberger; E G Hahn Journal: Ann Oncol Date: 2001-12 Impact factor: 32.976
Authors: P Flamen; S Stroobants; E Van Cutsem; P Dupont; G Bormans; N De Vadder; F Penninckx; L Van Hoe; L Mortelmans Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: M Margaret Kemeny; Sudeshna Adak; Bruce Gray; John S Macdonald; Thomas Smith; Stuart Lipsitz; Elin R Sigurdson; Peter J O'Dwyer; Al B Benson Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert Journal: Surgery Date: 1986-08 Impact factor: 3.982
Authors: Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: J V Vitola; D Delbeke; M P Sandler; M G Campbell; T A Powers; J K Wright; W C Chapman; C W Pinson Journal: Am J Surg Date: 1996-01 Impact factor: 2.565
Authors: A Wein; C Riedel; W Brückl; S Merkel; R Ott; B Hanke; U Baum; F Fuchs; K Günther; T Reck; T Papadopoulos; E G Hahn; W Hohenberger Journal: Oncology Date: 2003 Impact factor: 2.935
Authors: Ilia Gur; Brian S Diggs; Jesse A Wagner; Gina M Vaccaro; Charles D Lopez; Brett C Sheppard; Susan L Orloff; Kevin G Billingsley Journal: J Gastrointest Surg Date: 2013-10-04 Impact factor: 3.452
Authors: Sarah Y Boostrom; David M Nagorney; John H Donohue; Scott Harmsen; Kristine Thomsen; Florencia Que; Michael Kendrick; Kaye M Reid-Lombardo Journal: J Gastrointest Surg Date: 2009-09-16 Impact factor: 3.452